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Approximately 1% of the population has epilepsy, the most common neurological disorder. Moreover, people with epilepsy are 
more likely to die prematurely than those without epilepsy, and the most common epilepsy-related category of death is sudden 
unexpected death in epilepsy (SUDEP). Information concerning risk factors for SUDEP is conflicting, but potential risk factors 
include: age, early onset of epilepsy, duration of epilepsy, uncontrolled seizures, seizure frequency, number of antiepileptic drugs 
and winter temperatures. Additionally, the cause of SUDEP is still unknown; however, the most commonly suggested mechanisms 
are cardiac abnormalities during and between seizures. This review discusses the epidemiology, risk factors, etiology, and preventa-
tive measures in the management of SUDEP.
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EPILEPSY: GENERAL ASPECTS
Epilepsy is the most common serious neurological 
condition and approximately 50 million people worldwide 
have it.1 In the US, about 100,000 new cases of epilepsy 
are diagnosed.2,3 In the UK, between 1 in 140 and 1 in 200 
people (at least 300,000 people) are currently being treated 
for epilepsy.4 Epidemiological studies suggest that between 
70 and 80% of people developing epilepsy will go into 
remission, while the remaining patients continue to have 
seizures and are refractory to treatment with the currently 
available therapies.5,6 The most common risk factors 
for epilepsy are cerebrovascular disease, brain tumours, 
alcohol, traumatic head injuries, malformations of cortical 
development, genetic inheritance, and infections of the 
central nervous system. In resource-poor countries, endemic 
infections, such as malaria and neurocysticercosis, seem to 
be major risk factors.8
Epilepsies are characterized by spontaneous recurrent 
seizures, caused by focal or generalized paroxysmal changes 
in neurological functions triggered by abnormal electrical 
activity in the cortex.9 Because it involves hyperexcitable 
neurons, a basic assumption links the pathogenesis of 
epilepsy and the generation of synchronized neuronal activity 
with an imbalance between inhibitory [g-aminobutyric acid 
(GABA)-mediated] and excitatory (glutamate-mediated) 
neurotransmission, in favor of the latter.10 Seizures and 
epilepsy are usually divided into two groups: partial and 
generalized. Partial or focal seizures have clinical or EEG 
evidence of local onset and may spread to other parts of 
the brain during a seizure, while generalized seizures begin 
simultaneously in both cerebral hemispheres.8 Temporal 
lobe epilepsy (TLE) is the most common form of partial 
epilepsy, probably affecting at least 20% of all patients with 
epilepsy.11 It is the most common form of drug-refractory 
epilepsy.12 Atrophy of mesial temporal structures is well-
known to be associated with TLE and hippocampal sclerosis, 390
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which is the most frequent histological abnormality in this 
form of epilepsy.13
SUDDEN UNEXPECTED DEATH IN EPILEPSY
Epilepsy is associated with a two- to three-fold 
increase in mortality compared to the general population, 
and sudden unexpected death in epilepsy (SUDEP) is the 
most important direct epilepsy-related cause of death.8 
SUDEP is defined as non-traumatic and non-drowning 
death in patients with epilepsy that is sudden, unexpected, 
witnessed or unwitnessed, and with or without evidence of 
a seizure. Also in SUDEP, post mortem examination does 
not reveal a toxicological or anatomical cause of death 
(excluding documented status epilepticus).14 Comparisons of 
incidence estimates for SUDEP are difficult, since different 
definitions of SUDEP have been used, not all patients have 
a postmortem examination, and case ascertainment methods 
and source populations have varied.15 The incidence of 
SUDEP has been estimated to be 3.5/1000 person-years 
in a lamotrigine clinical trial,16 0.5-1.4/1000 person-years 
in people with treated epilepsy,17 5.9/1000 person-years in 
outpatients with epilepsy at a tertiary referral center,18 and 
0.35/1000 person-years in a population-based study.19 The 
National General Practice Study of Epilepsy (NGPSE), a 
community-based study in the United Kingdom, saw the first 
case of SUDEP after 11,000 person-years of follow-up,20 and 
the results of the Medical Research Council Antiepileptic 
Drug Withdrawal Study showed that SUDEP is a rare event 
among patients with epilepsy in remission.21 Information 
concerning risk factors for SUDEP is conflicting, but 
potential risk factors include: early adulthood,16 early onset 
of epilepsy,22 long duration of epilepsy,23 uncontrolled 
seizures (mainly in those with TLE),23,24 high seizure 
frequency,23-25 certain seizure types,23,26 higher numbers of 
AED22,23,27 and winter temperatures.28 Additionally, potential 
pathomechanisms for SUDEP are unknown, but it is very 
probable that cardiac arrhythmias during and between 
seizures, electrolyte disturbances, arrhythmogenic drugs 
or transmission of epileptic activity to the heart via the 
autonomic nervous system potentially play a role.29 
CARDIAC ABNORMALITIES AND SUDEP
By definition, the cause of death in SUDEP is currently 
unknown. A number of postmortem, ictal and interictal 
cardiac abnormalities do, however, suggest the possibility 
of seizure-induced cardiogenic SUDEP.29,30 
Postmortem examinations in people dying of SUDEP 
have found hearts that are dilated and heavier than 
expected16,29,31,32 and pulmonary edema in approximately 
50–86% of cases.16,26,29,32,33 Furthermore, others have 
described pathological changes in the hearts of those 
dying with SUDEP, including fibrosis of the walls of 
small coronary arteries, atrophy of cardiomyocytes, 
myofibrillar degeneration, edema of the conductive 
tissue and morphological abnormalities of the cardiac 
conduction system.26,29,31,34,35 These abnormalities may be 
the consequence of repeated hypoxemia and/or may be 
associated with the increase of catecholamines during an 
ictal sympathetic storm.29,31,34
Several studies have assessed the frequency and 
character of ictal cardiac rhythm during seizures,29,36,37 and 
the most compelling evidence derives from the presence of 
ictal arrhythmias.30 When ictal cardiorespiratory variables 
were recorded in people with epilepsy, an increase in heart 
rate in 91% of 41 seizures and a transient bradycardia in 
five seizures (four patients) were found.38 Another study 
evaluated the eletrocardiographic (ECG) changes during 
51 seizures in 43 patients with refractory epilepsy.39 This 
showed that 70% of patients had either ECG abnormalities 
(16%), tachycardias (30%), or both (23%) during the ictal 
and/or post-ictal period. These changes may all be relevant 
to the pathophysiology of SUDEP.
Results of interictal cardiac investigations have also 
been described. In one study, resting ECGs in 75 patients 
with epilepsy were compared with normal ECGs recorded 
in age-matched patients without cardiac or neurological 
disorders; ventricular rate, PR interval, QRS duration, and 
QT interval (corrected for heart rate) were compared.40 
Those with epilepsy had higher heart rates and longer QT 
durations than the age-matched controls. Heart rate and 
QT duration were, however, not outside the normal range. 
Others investigated whether patients with drug refractory 
epilepsy have cardiovascular abnormalities that might be 
related to sudden death.41 Twenty-three subjects underwent 
comprehensive cardiovascular evaluations (ECG, Holter-
monitoring, echocardiography, ergometric exercise test 
and myocardial scintigraphy; if abnormalities were found, 
coronary angiography was also performed) before and during 
video-EEG monitoring. ST-segment depression was found in 
40%, and this was associated with a higher maximum heart 
rate during seizures, suggesting that cardiac ischemia may 
occur in these patients. Although interictal changes in heart 
rate variability have been described in patients with epilepsy, 
their contribution to SUDEP remains to be determined.
PREVENTATIVE MEASURES FOR SUDEP BE-
YOND THERAPIES
Preventative measures other than medical and surgical 
therapies could be useful in the prevention of SUDEP. 391
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Although the availability of pharmacological treatment 
of epilepsies has expanded, antiepileptic drugs are still 
limited in clinical efficacy. Genetic, environmental and 
social factors, among others, can contribute to the inefficacy 
of therapeutic outcome in people with epilepsy. Among 
these factors, nutritional aspects such as omega-3 fatty 
acid deficiency may play an interesting role. Substantial 
evidence from epidemiological and case-control studies 
indicates that omega-3 reduces the risk of cardiovascular 
mortality, particularly sudden cardiac death.42 Following this 
reasoning, as omega-3 fatty acids per se have been shown 
to reduce cardiac arrhythmias and sudden cardiac deaths, it 
was hypothesised that omega-3 fatty acid supplementation 
in patients with refractory seizures may reduce seizures 
and seizure-associated cardiac arrhythmias, and hence, 
also SUDEP.4 Concerning the cardioprotective effects of 
omega-3, it has long been believed that a daily intake of 
3000 to 4000 mg of fish oil supplements or 2 to 3 servings of 
fatty fish per week are safe and effective in adults in general, 
including those with neurological diseases.43 It is very 
important to emphasise, however, that nutritional therapy, 
including omega-3 supplementation, is not a substitute for 
anticonvulsant medications. 
Exposure to low temperatures is considered one of the 
main risk factors for cardiovascular abnormalities and hence, 
sudden death.44 There are several findings that may explain 
the increase in cardiac events in cold temperatures: 1) 53% 
more cases of acute myocardial infarction are reported 
during the winter compared with the summer.45 Most reports, 
but not all, have demonstrated a significant winter increase 
in cardiovascular abnormalities and cardiac death, especially 
in the northern hemisphere where there are extreme winter 
temperatures.46,47 An increase in sudden cardiac death rate 
has, however, also been reported in the winter in regions 
where the winters are mild.48,49 2) During the winter, 
increases in haemoconcentration (erythrocyte count, 
plasma cholesterol, and plasma fibrinogen levels) have been 
reported, which could contribute to arterial thrombosis.50 In 
this way, rapid coronary deaths could result from rupture of 
atheromatous plaques during hemodynamic stress related to 
hypertension and cold-induced coronary spasm.51,52 3) Cold 
weather can induce a higher systemic vascular resistance 
with an increase in blood pressure, thus increasing oxygen 
demand.53 During a four-year period, the influence of climate 
on blood pressure in 53 patients with end-stage renal disease 
treated with haemodialysis was investigated. The authors 
showed that the mean systolic and diastolic blood pressures 
were highest during the winter (systolic 153 [SE 3] and 
diastolic 82 [SE 2] mm Hg) and lowest during the summer 
(systolic 141 [SE 3] and diastolic 75 [SE 2] mm Hg). 4) The 
winter temperatures may be associated with flu season, and 
an increase in upper respiratory tract infections could place 
stress on the heart.54 One review noted that the incidence 
of acute myocardial infarction and atherosclerotic stroke 
and the incidence of upper respiratory infections (38% of 
which are due to influenza) both peak in the winter months. 
It was suggested that, as studies have shown that influenza 
vaccination is associated with a 50% reduction in incidence 
of cardiovascular abnormalities and sudden cardiac death, 
much of this pathology could be prevented by yearly 
influenza vaccination.55 
Taking these data into consideration, we believe that cold 
weather could be considered a new potential risk factor for 
sudden cardiac death in patients with epilepsy.28 Moreover, 
there is an urgent need for several studies (large-scale, 
prospective, community-based and international) of sudden 
cardiac death in epilepsy to explore the risk factors and help 
plan preventative strategies. In the meantime, the use of 
some medical or non-medical therapies may help to prevent 
sudden cardiac death in epilepsy. Along those lines, Kloner 
(2004)54 described some very interesting common-sense 
and prudent tactics that physicians should consider during 
the winter time (termed “Merry Christmas Coronary” and 
“Happy New Year Heart Attack”), especially for patients 
with established cardiac disease or for those with known risk 
factors for cardiac disease: 1) instruct patients to avoid delay 
in seeking medical attention; 2) examine patients if possible, 
rather than relying upon healthcare providers not familiar 
with the patients; 3) ensure that coronary care units and 
emergency departments are adequately staffed; 4) instruct 
patients to avoid the known triggers for acute myocardial 
infarction, such as excess physical exertion (especially 
shovelling show), overeating, lack of sleep, emotional 
stress, illegal drugs and anger; 5) modify and treat known 
cardiovascular risk factors; 6) consider aspirin or ß-blockers, 
or both, if appropriate; 7) instruct patients to avoid exposure 
to severely cold temperatures; 8) consider flu shots when 
appropriate.
Others have suggested, since winter mortality in the UK 
is now not primarily caused by failure to heat homes, the 
reduction of outdoor cold stress, such as by heating waiting 
areas for public transport, should be considered.57
Finally, several suggestions have been made concerning 
the mechanisms behind SUDEP, most involving speculation 
about the possible role of autonomic effects such as 
cardiorespiratory disturbances. It has been believed 
that cardiovascular diseases are often associated with 
overactivity of the sympathetic nervous system58 and 
that increases in physical activity produce beneficial 
effects on the cardiovascular system in both normal and 
diseased individuals via alteration of neural control of the 
circulation.59,60 These effects include reductions in blood 392
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pressure and sympathetic outflow in humans61 as well as 
in animal models of exercise training.62,63 Since morbidity 
and mortality in cardiovascular disease are often associated 
with elevation of sympathetic nervous system activity,64 the 
beneficial effects of physical activity are probably related, 
in part, to reduction of sympathetic activity. A recent study 
by our group evaluated the heart rate, in vivo (ECG) and 
isolated ex vivo preparation (Langendorf preparation) of 
rats with epilepsy.65 The results showed differences in the 
mean heart rate in vivo, but surprisingly, no differences in 
heart rate could be observed in the isolated ex vivo situation, 
suggesting a central nervous system modulation of the heart 
that could explain SUDEP.65 
Taking these findings together, it is very reasonable 
to think that regular physical activity is able to attenuate 
sympathetic nervous system activity, cardiac abnormalities and 
hence SUDEP. Furthermore, it is clear that premature mortality 
is increased in patients with epilepsy, particularly in those with 
more severe seizures,15 and it is generally acknowledged that 
the incidence of cardiac abnormalities between seizures is the 
very probable cause of SUDEP.15,29 Since physical activity 
has been considered to have anticonvulsant effects,66-68 it is 
possible to propose that regular physical activity may attenuate 
the frequency of seizures and cardiac abnormalities that could 
culminate in SUDEP.
In conclusion, as reported by others,69 clarification of risk 
factors and establishment of the mechanisms of SUDEP are 
important for establishing preventative measures for SUDEP 
and for striving for the best control of seizures. However, 
it is conceivable that encouraging patients with epilepsy 
worldwide to receive non-pharmacological treatments will 
lead to substantial public-health benefits.
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